2.1
Idelalisib (Zydelig, Gilead) has a marketing authorisation 'as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment'.
2 Information about idelalisib
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
Idelalisib is administered orally at a dose of 150 mg, twice daily. Treatment is continued until disease progression or unacceptable toxicity.
Price
2.3
The list price for idelalisib is £3,114.75 per pack of 60 x 150 mg film-coated tablets (excluding VAT, company submission).
2.4
The company has a commercial arrangement for idelalisib, which would apply if the technology had been recommended.